ABOS Acumen Pharmaceuticals Inc

USD 2.82 0.00 0
Icon

Acumen Pharmaceuticals Inc (ABOS) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 2.82

0.00 (0.00)%

USD 0.17B

0.87M

USD 15.00(+431.91%)

USD 7.50 (+165.96%)

Icon

ABOS

Acumen Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 2.82
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.17B

USD 7.50 (+165.96%)

USD 2.82

Acumen Pharmaceuticals Inc (ABOS) Stock Forecast

Show ratings and price targets of :
USD 15.00
(+431.91%)

Based on the Acumen Pharmaceuticals Inc stock forecast from 1 analysts, the average analyst target price for Acumen Pharmaceuticals Inc is USD 15.00 over the next 12 months. Acumen Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Acumen Pharmaceuticals Inc is Slightly Bullish , which is based on 5 positive signals and 4 negative signals. At the last closing, Acumen Pharmaceuticals Inc’s stock price was USD 2.82. Acumen Pharmaceuticals Inc’s stock price has changed by +22.08% over the past week, +6.82% over the past month and -55.10% over the last year.

No recent analyst target price found for Acumen Pharmaceuticals Inc
No recent average analyst rating found for Acumen Pharmaceuticals Inc

Company Overview Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gam...Read More

https://acumenpharm.com

427 Park Street, Charlottesville, VA, United States, 22902

51

December

USD

USA

Adjusted Closing Price for Acumen Pharmaceuticals Inc (ABOS)

Loading...

Unadjusted Closing Price for Acumen Pharmaceuticals Inc (ABOS)

Loading...

Share Trading Volume for Acumen Pharmaceuticals Inc Shares

Loading...

Compare Performance of Acumen Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ABOS

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Acumen Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD127.00B 31.94 20.00

ETFs Containing ABOS

Symbol Name ABOS's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Acumen Pharmaceuticals Inc (ABOS) Stock

Based on ratings from 1 analysts Acumen Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and hold ratings.

Unfortunately we do not have enough data on ABOS's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for ABOS is USD 15.00 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 15.

ABOS stock's Price/Earning ratio is 3.26. Our analysis grades ABOS stock's Price / Earning ratio at F. This means that ABOS stock's Price/Earning ratio is above 42.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ABOS may be fairly valued for its sector

The last closing price of ABOS's stock was USD 2.82.

The most recent market capitalization for ABOS is USD 0.17B.

Based on targets from 1 analysts, the average taret price for ABOS is projected at USD 15.00 over the next 12 months. This means that ABOS's stock price may go up by +431.91% over the next 12 months.

We can't find any ETFs which contains Acumen Pharmaceuticals Inc's stock.

As per our most recent records Acumen Pharmaceuticals Inc has 51 Employees.

Acumen Pharmaceuticals Inc's registered address is 427 Park Street, Charlottesville, VA, United States, 22902. You can get more information about it from Acumen Pharmaceuticals Inc's website at https://acumenpharm.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...